Dihydrocodeine Bitartrate
FDA-approved product (capsule, oral).
- Registered studies
- 3
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBL- WHO therapeutic group
- Natural opium alkaloids
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against K. pneumoniae, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA42.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli38.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae45.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- M. tuberculosis42.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
3registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Dihydrocodeine Bitartrate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Ergotamine TartrateExisting use: Headache, Migraine disorder41.3% AI-predicted activityagainst K. pneumoniae10 registered studies
- InavolisibExisting use: Breast cancer, Breast neoplasm41.2% AI-predicted activityagainst K. pneumoniae36 registered studies
- Rimegepant SulfateExisting use: Migraine disorder40.9% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Pasireotide PamoateExisting use: Acromegaly, Pituitary-dependent Cushing's disease40.9% AI-predicted activityagainst K. pneumoniae1 registered study
- Terazosin HydrochlorideExisting use: Benign prostatic hyperplasia40.9% AI-predicted activityagainst K. pneumoniae41 registered studies
- Avatrombopag MaleateExisting use: Hemorrhage, Liver disease, Thrombocytopenia40.8% AI-predicted activityagainst K. pneumoniae6 registered studies
- LinagliptinExisting use: Diabetes mellitus, Type 2 diabetes mellitus40.6% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Rocuronium BromideExisting use: Other quaternary ammonium compounds40.4% AI-predicted activityagainst K. pneumoniae50+ registered studies
- BiotinExisting use: Anemia (phenotype), Chronic kidney disease, Iron deficiency anemia and 1 more40.3% AI-predicted activityagainst K. pneumoniae50+ registered studies
- BuprenorphineExisting use: Chronic pain, Drug dependence, Opioid dependence and 4 more40.2% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Vinorelbine TartrateExisting use: Cancer, Neoplasm40.1% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Trilaciclib DihydrochlorideExisting use: Small cell lung carcinoma40.0% AI-predicted activityagainst K. pneumoniae2 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Comparison of the Efficacy, Tolerability and Safety of actiTENS to Those of Level 2 Analgesic Treatments.
NCT03902340 · start 2018-12-19
Registered record
- Registry ID
- NCT03902340
- Conditions
- Knee Osteoarthritis
- Interventions
- ActiTENS; Level 2 Analgesic Treatments
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Unknown
- Start
- 2018-12-19
- Completion
- 2019-10-31
- Enrolment
- 110
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionKnee OsteoarthritisInterventionActiTENS; Level 2 Analgesic TreatmentsPhaseNot applicableRegistry statusUnknownRandomized Controlled Double Blind Trial of Short vs Long Acting Dihydrocodeine in Chronic Non-malignant Pain
NCT00547885 · start 2007-10
Registered record
- Registry ID
- NCT00547885
- Conditions
- Pain
- Interventions
- Dihydrocodeine
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2007-10
- Completion
- 2012-06
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPainInterventionDihydrocodeinePhasePhase 4Registry statusCompletedA Study to Evaluate the Safety and Effectiveness of Fentanyl-TTS Compared to Weak Opioids in Patients With Moderate to Severe Chronic Cancer Pain Previously Treated With NSAIDS (Non-steroidal Anti-inflammatory Drugs).
NCT00576017 · start 2003-10
Registered record
- Registry ID
- NCT00576017
- Conditions
- Pain
- Interventions
- Fentanyl-TTS
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2003-10
- Completion
- 2005-03
- Enrolment
- 19
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPainInterventionFentanyl-TTSPhasePhase 4Registry statusCompleted